Rangatira buys controlling stake in lab equipment firm Bio-Strategy

Tue, 07 Jul 2015

By Paul McBeth July 7 (BusinessDesk) - Rangatira Investments, the Wellington-based investment firm, bought 70 percent of lab equipment firm Bio-Strategy for an undisclosed sum, to help the firm expand into new markets and broaden its offering. The investment firm bought the stake from Bio-Strategy directors Graeme Thompson and Robert Lyon, who will keep 30 percent of the firm and remain executive directors of the company, Rangatira said in a statement. Bio-Strategy sources products from high-tech manufacturers which it then supplies to cl...

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

Property FREE
Money Answers: how much mortgage can I actually afford?
Frances Cook | Sat, 25 Jun 2022

This week, readers ask how they should decide as a family what they can afford in terms of buying a house – and just because you can, should you?

The eyes have it
The Economist | Sat, 25 Jun 2022

Short-sightedness used to be rare. Now it's growing across the globe. Tim Cross, The Economist's technology editor, investigates its rapid rise.

On the Money
On the Money: Don Braid, Fletcher, Steve Newman and more
Victoria Young | Sat, 25 Jun 2022

OTM this week: A bit of matchy-matchy for Don Braid, the reopening of Parliament's lawns, Eroad, Fletcher and more. 

Investments to sustain the momentum of building in NZ

Classic Capital has opened its Land & Build fund to qualified wholesale and eligible investors.

High water marks: Watercare raises the tide on sustainability

The No.1 barrier to decarbonisation for NZ organisations is accurate measurement, says Microsoft’s Accelerating the Journey to Net Zero report.